Metastatic Breast Cancer: Symptoms, Treatment, Research
What is metastatic breast cancer? Learn more about stage 4 breast cancer and what BCRF is doing to accelerate lifesaving research
Metastatic breast cancer can be treated with more therapies than ever before. However, it is still not curable, which makes it an urgent priority for Breast Cancer Research Foundation (BCRF) researchers.
In the U.S. today, there are an estimated 170,000 women living with metastatic breast cancer, also called stage 4 breast cancer or advanced breast cancer. It is the leading cause of breast cancer deaths.
Whether you have just been diagnosed, are living with metastatic breast cancer, or are supporting someone who is, this guide explains how the disease spreads, the symptoms to watch for, how it is diagnosed and treated, and the research bringing new options to patients.
Key Takeaways
- Metastatic breast cancer (stage 4) occurs when breast cancer spreads to other parts of the body; it is treatable but not yet curable.
- Symptoms vary by where the cancer has spread, with common signs including bone pain, headaches or vision changes, jaundice, chest pain, or persistent cough.
- More treatment options exist than ever before, including hormone therapy, chemotherapy, targeted therapies, immunotherapy, and radiation or surgery for symptom relief.
- BCRF is the largest private funder of metastatic breast cancer research in the world, driving major breakthroughs and expanding treatment options through global studies and innovative science.
What is metastatic breast cancer?
Metastatic breast cancer is when cancer that initially started in the breast spreads to other areas of the body. It is classified as stage 4, the most advanced stage of the disease. Breast cancer that has spread only to the lymph nodes near the breast is not considered metastatic, though it may be called locally advanced.
Metastasis occurs when breast cancer cells break away from the original tumor or nearby lymph nodes (found under the arm, inside the breast, and near the collarbone). The breast tumor cells then enter the bloodstream or lymphatic system, travel to other organs, and begin to grow. Doctors most commonly find breast cancer metastases in the bones, lungs, liver, and/or brain.
Only 6-10% of women are first diagnosed with stage 4 breast cancer, called de novo metastatic breast cancer. However, nearly 30% of women diagnosed with early-stage breast cancer (stages 1-3) will see their disease metastasize.
About one in three breast cancer survivors will be diagnosed with a recurrence (cancer that has come back after a previous diagnosis and treatment), which can spread to other organs in the body. Recurrence rates vary and depend on factors such as subtype, age, and access to and adherence to treatment. Alarmingly, in recent years, there has been a rise in metastatic breast cancer diagnoses in younger women.
Metastatic breast cancer symptoms
The early signs of metastatic breast cancer may vary depending on how far the breast cancer has spread and what area/type of tissue the cancer has invaded. Non-specific symptoms of stage 4 breast cancer can include fatigue, weight loss, and poor appetite, but these may also be caused by medication, depression, and other conditions.
The table below lists the most common metastatic breast cancer symptoms, grouping them by where the cancer has spread.
| Where it has spread | Common symptoms |
|---|---|
| Bone | Bones are more easily fractured or broken; swelling; sudden, noticeable progressive bone pain; new or worsening back or neck pain; numbness or weakness in the legs; trouble controlling the bladder or bowels; thirst, constipation, nausea, or confusion from high calcium levels in the blood (hypercalcemia) |
| Brain | Persistent and progressively worsening headache; problems with speech or vision; vomiting or nausea; seizures; behavioral changes; memory problems |
| Liver | Itchy skin or rash; jaundice; abdominal pain, vomiting, or nausea; abnormally high liver enzymes in the blood |
| Lung | Chest pain; chronic cough or shortness of breath; abnormal chest X-ray |
| Skin and chest wall | Firm, usually painless lumps in or just under the skin, most often on the chest near the original tumor or surgical scar; redness, a rash, or thickened skin that can look like an infection; open sores that bleed or do not heal |
Back or neck pain together with numbness or weakness in the legs can mean cancer in the spine is pressing on the spinal cord. This is a medical emergency, so seek medical treatment immediately.
If you are currently undergoing treatment for breast cancer and experience any of these symptoms, talk to your doctor right away. Early detection can ensure you’re getting the best treatment for metastatic breast cancer. If you are a breast cancer survivor—and/or if members of your immediate family have been impacted by the disease—and you begin experiencing any of the above symptoms, be sure to inform your doctor of your personal or family history of breast cancer.
How is metastatic breast cancer diagnosed?
If your doctor has reason to suspect your disease has metastasized (or you have de novo metastatic breast cancer), they may perform follow-up tests. These include imaging tests, blood tests, and biopsies of the suspected metastatic lesion (growth).
As seen in the table below, the tests your doctor orders depend on where they suspect the cancer has spread.
| Suspected Site | Tests doctors may use |
|---|---|
| Brain | A brain MRI and, in rare cases, when possible, a brain biopsy |
| Bone | MRI, CT, or PET scans followed by a biopsy; bone scans or X-rays; and blood tests to specifically diagnose metastatic breast cancer in bones |
| Lung | MRI, CT, or PET scans followed by a biopsy; bronchoscopy or a mucus exam |
| Liver | MRI, CT, or PET scans followed by a biopsy; liver function tests or an ultrasound |
Metastatic breast cancer treatment
While there is no cure for metastatic breast cancer, there are a variety of treatment options that prolong lives. Treatment is usually ongoing, and its goals are to control the cancer for as long as possible, ease symptoms, and protect quality of life.
After a metastatic breast cancer diagnosis, doctors may use several treatment approaches. This depends on where the cancer has spread, its characteristics (such as hormone receptor or HER2 status), and prior treatments.
The most common treatments for stage 4 breast cancer are systemic, meaning they travel through the bloodstream to reach cancer cells throughout the body.
Hormone therapy
Molecularly targeted drugs for breast cancer — including Nolvadex® (tamoxifen), Faslodex® (fulvestrant), or aromatase inhibitors such as Femara® (letrozole) — can help shrink or slow the growth of hormone receptor (HR)–positive metastatic breast cancer.
Newer oral drugs that block or break down the estrogen receptor, such as ORSERDU® (elacestrant), Inluriyo® (imlunestrant), Veppanu (vepdegestrant) and Etcamah (camizestrant), are now available. These can help treat some people whose cancer develops an ESR1 mutation, a common cause of resistance to earlier hormone therapy.
Chemotherapy
Medications such as Adriamycin® (doxorubicin), Xeloda® (capecitabine), and Taxol® (paclitaxel) may be used alone or in combination with other drugs to treat metastatic breast cancer that is growing quickly or is present in significant amounts within organs.
Targeted therapy and immunotherapy
There are also other therapies that target specific characteristics of cancer cells, such as proteins that allow cancer to grow unchecked. Unlike chemotherapy, which does not distinguish between cancerous and non-cancerous cells and therefore can harm both, these targeted therapies are generally less likely to harm normal cells. There are more than a dozen such FDA-approved targeted therapies for metastatic breast cancer. They can be used alone or in combination with chemotherapy to treat specific breast cancer subtypes, as shown in the table below.
| Treatment type | Examples | Main subtypes |
|---|---|---|
| HER2-targeted antibodies: target HER2 and leverage the power of the patients’ immune system to fight cancer | Herceptin® (trastuzumab), Perjeta® (pertuzumab), Margenza® (margetuximab) | HER2-positive |
| HER2 inhibitor pills: block HER2 signals inside cancer cells | Nerlynx® (neratinib maleate), Tukysa® (tucatinib) | HER2-positive, including cancer that has spread to the brain (Tukysa) |
| Antibody-drug conjugates: recognize specific targets on cancer cells and deliver toxic drugs directly to the tumor | HER2-targeted Enhertu® (trastuzumab deruxtecan) and Kadcyla® (trastuzumab emtansine); TROP-2-targeted Trodelvy® (sacituzumab govitecan) and Datroway® (datopotamab deruxtecan) | HER2-positive and HER2-low (Enhertu); HER2-positive (Kadcyla); HR-positive/HER2-negative and triple-negative (Trodelvy, Datroway) |
| PARP inhibitors: target the PARP protein, an important enzyme involved in DNA repair | Lynparza® (olaparib), Talzenna® (talazoparib) | HER2-negative, in people with inherited BRCA1 or BRCA2 mutations |
| CDK4/6 inhibitors: interrupt specific enzymes to slow or stop cancer cells from growing | Ibrance® (palbociclib), KISQALI® (ribociclib), Verzenio® (abemaciclib) | HR-positive, with hormone therapy |
| PI3K, AKT and mTOR pathway inhibitors: block a growth pathway that is often overactive in HR-positive cancer | Piqray® (alpelisib), Itovebi® (inavolisib), Truqap® (capivasertib), Revtorpyk (gedatolisib) | HR-positive/HER2-negative, often with PIK3CA, AKT1 or PTEN alterations |
| Immune checkpoint inhibitors: help the immune system recognize and attack cancer cells | Keytruda® (pembrolizumab) | Triple-negative that tests positive for the PD-L1 protein |
Surgery and radiation for symptom relief
Surgery may not always be the best option because it is unlikely to remove all cancer cells. However, some doctors recommend targeted surgery and/or radiation to alleviate pain or other specific symptoms. In addition, although doctors don’t commonly use other localized therapies (such as radiation therapy or ablation) to treat metastatic breast cancer, they may use them in certain circumstances, particularly when:
- Tumors press on critical areas of the brain or spinal cord
- Bone metastases weaken the bone so much that it poses a risk of fracture
- Lesions in the lungs make it hard to breathe
- Tumors interfere with normal liver function
Every treatment plan is based on individual needs. What works for one person might not work for another. Your medical team is your best guide.
BCRF’s focus on metastatic breast cancer research
BCRF is the largest private funder of metastatic breast cancer research in the world. This year, the Foundation is dedicating almost $23.8 million across 102 projects to this area of study.
“Virtually all deaths from cancer are from metastases—we lose about 42,000 people in the U.S. alone to metastatic breast cancer each year,” says Dr. Dorraya El-Ashry, BCRF Chief Scientific Officer. “That’s why metastatic breast cancer research remains a high priority at BCRF. These projects will help us understand the full spectrum of metastatic disease in order to both effectively treat it and ultimately prevent it altogether.”
BCRF investigators are examining all aspects of stage 4 breast cancer, including:
- Understanding the biology of metastasis and identifying distinct molecules that facilitate this process
- Identifying treatment targets and mechanisms of resistance
- Developing novel therapies or treatment combinations to treat the disease
- Improving the quality of life for patients living with metastatic breast cancer
- Understanding the characteristics of metastatic breast cancer in Black patients to improve our understanding of their disparate outcomes and inform novel treatment strategies for this patient population
BCRF has invested over $48 million in large initiatives through the Evelyn H. Lauder Founder’s Fund for Metastatic Breast Cancer Research. Studies funded by this initiative produced an experimental model system that precisely mimics human breast metastases and an open-access online database of metastases models, which are both available to the research community. The fund also supports AURORA EU, led by the Breast International Group (BIG), and AURORA US, run through the Translational Breast Cancer Research Consortium. Together, they form the largest global effort to compare primary and metastatic breast cancer, using tumor and blood samples to learn how the disease progresses and why it does or does not respond to treatment. Both published their first findings in 2019.
Breakthrough discoveries and new treatments
There is much to be hopeful about in metastatic breast cancer research, especially recently. The pace of research in MBC has been accelerating. Since 2015, the FDA has approved 19 new drugs for this disease based on research and clinical findings from BCRF investigators and others, many of which are described in the treatment section above.
A turning point for HER2-low breast cancer
At the 2022 American Society of Clinical Oncology meeting, researchers, clinicians, and others heralded astonishing results from the DESTINY-Breast04 trial. Investigators found that the drug Enhertu® significantly improved progression-free survival for patients with HER2-low metastatic cancer. Soon after, the FDA approved Enhertu for advanced HER2-low breast cancer. BCRF researchers and others continue working to more precisely define HER2-low so that more people can benefit from treatment with this drug. “We’ve opened up a new targetable population of patients within breast cancer,” lead investigator Dr. Shanu Modi told BCRF in an interview.
New metastatic breast cancer treatments in 2026
Discoveries are still arriving at a steady pace. In 2026 alone, the FDA approved three new drugs for metastatic breast cancer and expanded the use of five others. Many are matched to specific tumor features, such as an ESR1 or PIK3CA mutation, so testing increasingly shapes which options a patient can consider.
| Drug | Approved for | Type |
|---|---|---|
| Veppanu (vepdegestrant) | ER-positive/HER2-negative, ESR1-mutated advanced or metastatic breast cancer after at least one line of endocrine therapy. The first approved drug of its kind, a protein degrader. | New drug |
| Revtorpyk (gedatolisib) with Faslodex®, with or without Ibrance® | HR-positive/HER2-negative advanced or metastatic breast cancer without a PIK3CA mutation, after endocrine therapy | New drug |
| Etcamah (camizestrant) with a CDK4/6 inhibitor | HR-positive/HER2-negative advanced or metastatic breast cancer when a blood test finds an ESR1 mutation during first treatment, before scans show growth (accelerated approval) | New drug |
| Trodelvy®, alone or with Keytruda® | First-line treatment of metastatic triple-negative breast cancer | Expanded use |
| Datroway® | Metastatic triple-negative breast cancer in patients who are not eligible for immunotherapy | Expanded use |
| Ibrance® with HER2-targeted and endocrine therapy | Maintenance treatment for HR-positive/HER2-positive metastatic breast cancer | Expanded use |
| Tukysa® with Herceptin® and Perjeta® | Maintenance treatment for HER2-positive metastatic breast cancer | Expanded use |
| Inluriyo® with Verzenio® | ER-positive/HER2-negative, ESR1-mutated advanced or metastatic breast cancer after endocrine therapy | Expanded use |
What’s next for metastatic breast cancer treatment
More developments in treatment are on the way. The FDA has accepted an application for giredestrant, another oral drug that targets the estrogen receptor, for ESR1-mutated advanced breast cancer. The company testing the targeted therapy medication gedatolisib has applied to extend its use to tumors with a PIK3CA mutation. Approvals like Etcamah’s also point to a broader shift: blood tests that detect resistance before scans show the cancer growing, so treatment can change sooner.
Related: How Far Has Metastatic Breast Cancer Research Come?
Looking ahead: advancing toward a future without metastatic breast cancer
Research is revealing that some metastases can be prevented in certain patients with HER2-positive breast cancer.. Research is the reason we are finally seeing real momentum in metastatic breast cancer research. We are on the cusp of groundbreaking developments in stage 4 breast cancer research, and BCRF is committed to leading the way.
Support the research driving these discoveries. Donate, start a fundraiser, or explore other ways to give and help fund the science that’s bringing new treatment options to people living with metastatic breast cancer.
Frequently asked questions
Metastatic breast cancer is treatable but not yet curable. Many people live with it for years as an ongoing condition, moving through different treatments as needed. Thanks to research funded by organizations like BCRF, new therapies are helping many people live longer while maintaining quality of life.
According to the American Cancer Society, the five-year relative survival rate for breast cancer that has already spread to distant organs when first diagnosed is 32%. Life expectancy differs for each person, and some people live 10 years or more with metastatic breast cancer. Subtype, where the cancer has spread, and how it responds to treatment all affect the outlook.
Yes, for many people. Chemotherapy is often part of the treatment for metastatic breast cancer, especially when the cancer is growing quickly, affects organs, or no longer responds to hormone or targeted therapy. It can shrink tumors and ease symptoms. Effectiveness depends on the individual case, so your medical team can explain whether it fits your situation.
Yes. Breast cancer can return in distant organs many years after treatment ends, especially in estrogen receptor (ER)-positive disease. A large analysis of nearly 63,000 women with ER-positive breast cancer found that, after five years of hormone therapy, distant recurrences continued at a steady rate up to 20 years after diagnosis.
Many newer treatments work only for cancers with specific features, so test results help guide treatment choices. ASCO guidelines recommend offering a biopsy of the metastases, when possible, to recheck hormone receptor and HER2 status, which can change. For ER-positive, HER2-negative disease, testing for ESR1 mutations at progression is also recommended.